• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

轴向位置带有卤代乙酸根配体的铂(IV)前药的稳定性

On the stability of Pt(IV) pro-drugs with haloacetato ligands in the axial positions.

作者信息

Wexselblatt Ezequiel, Raveendran Raji, Salameh Sawsan, Friedman-Ezra Aviva, Yavin Eylon, Gibson Dan

机构信息

Institute for Drug Research, School of Pharmacy, The Hebrew University, Jerusalem, 91120 (Israel).

出版信息

Chemistry. 2015 Feb 9;21(7):3108-14. doi: 10.1002/chem.201405467. Epub 2014 Dec 21.

DOI:10.1002/chem.201405467
PMID:25529335
Abstract

The design of Pt(IV) pro-drugs as anticancer agents is predicated on the assumption that they will not undergo substitution reactions before entering the cancer cell. Attempts to improve the cytotoxic properties of Pt(IV) pro-drugs included the use of haloacetato axial ligands. Herein, we demonstrate that Pt(IV) complexes with trifluoroacetato (TFA) or dichloroacetato (DCA) ligands can be unstable under biologically relevant conditions and readily undergo hydrolysis, which results in the loss of the axial TFA or DCA ligands. The half-lives for Pt(IV) complexes with two TFA or DCA ligands at pH 7 and 37 °C range from 6 to 800 min, which is short relative to the duration of cytotoxicity experiments that last 24-96 h. However, complexes with two monochloroacetato (MCA) or acetato axial ligands are stable under biologically relevant conditions. The loss of the axial ligands depends primarily on the electron-withdrawing strength of the axial ligands, but also upon the nature of the equatorial ligands. We were unable to find obvious correlations between the structures of the Pt(IV) complexes and the rates of decay of the parent compounds. The X-ray crystal structures of the bis-DCA and bis-MCA Pt(IV) derivatives of oxaliplatin did not reveal any significant structural differences that could explain the observed differences in stability.

摘要

将铂(IV)前药设计为抗癌剂的前提是假设它们在进入癌细胞之前不会发生取代反应。改善铂(IV)前药细胞毒性的尝试包括使用卤代乙酸轴向配体。在此,我们证明了含有三氟乙酸根(TFA)或二氯乙酸根(DCA)配体的铂(IV)配合物在生物学相关条件下可能不稳定,并容易发生水解,这会导致轴向TFA或DCA配体的丢失。在pH 7和37°C条件下,含有两个TFA或DCA配体的铂(IV)配合物的半衰期为6至800分钟,相对于持续24 - 96小时的细胞毒性实验持续时间而言较短。然而,含有两个一氯乙酸根(MCA)或乙酸根轴向配体的配合物在生物学相关条件下是稳定的。轴向配体的丢失主要取决于轴向配体的吸电子强度,但也取决于赤道配体的性质。我们未能在铂(IV)配合物的结构与母体化合物的衰变速率之间找到明显的相关性。奥沙利铂的双DCA和双MCA铂(IV)衍生物的X射线晶体结构未显示出任何能解释所观察到的稳定性差异的显著结构差异。

相似文献

1
On the stability of Pt(IV) pro-drugs with haloacetato ligands in the axial positions.轴向位置带有卤代乙酸根配体的铂(IV)前药的稳定性
Chemistry. 2015 Feb 9;21(7):3108-14. doi: 10.1002/chem.201405467. Epub 2014 Dec 21.
2
Platinum(IV) prodrugs with haloacetato ligands in the axial positions can undergo hydrolysis under biologically relevant conditions.轴向位置带有卤乙酸配体的铂(IV)前药可以在生物学相关条件下发生水解。
Angew Chem Int Ed Engl. 2013 Jun 3;52(23):6059-62. doi: 10.1002/anie.201300640. Epub 2013 May 17.
3
Investigation of the Inertness to Hydrolysis of Platinum(IV) Prodrugs.铂(IV)前药水解惰性的研究。
Inorg Chem. 2016 Feb 15;55(4):1580-6. doi: 10.1021/acs.inorgchem.5b02484. Epub 2016 Jan 26.
4
Importance of platinum(II)-assisted platinum(IV) substitution for the oxidation of guanosine derivatives by platinum(IV) complexes.铂(II)辅助的铂(IV)取代对铂(IV)配合物氧化鸟苷衍生物的重要性。
Inorg Chem. 2008 Feb 18;47(4):1352-60. doi: 10.1021/ic701868b. Epub 2008 Jan 26.
5
Potentiation of mitochondrial dysfunction in tumor cells by conjugates of metabolic modulator dichloroacetate with a Pt(IV) derivative of oxaliplatin.代谢调节剂二氯乙酸与奥沙利铂的铂(IV)衍生物的共轭物对肿瘤细胞线粒体功能障碍的增强作用
J Inorg Biochem. 2016 Mar;156:89-97. doi: 10.1016/j.jinorgbio.2015.12.003. Epub 2015 Dec 31.
6
Synthesis, Structure, and Cytotoxicity of Oxaliplatin-Based Platinum(IV) Anticancer Prodrugs Bearing One Axial Fluoride.基于奥沙利铂的含一个轴向氟的铂(IV)抗癌前药的合成、结构和细胞毒性。
Inorg Chem. 2018 Jul 16;57(14):8227-8235. doi: 10.1021/acs.inorgchem.8b00706. Epub 2018 Jun 26.
7
Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.轴向和赤道配体介导的1,2-二氨基环己烷铂(IV)配合物的细胞毒性和细胞药理学调节
Cancer Res. 1993 Oct 1;53(19):4567-72.
8
Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.轴向和赤道配体对反式-1R,2R-二氨基环己烷铂(IV)配合物抗肿瘤活性的调节作用。
Anticancer Drug Des. 1994 Apr;9(2):139-51.
9
The influence of different carbonate ligands on the hydrolytic stability and reduction of platinum(IV) prodrugs.不同碳酸配体对铂(IV)前药的水解稳定性和还原的影响。
Dalton Trans. 2022 Jan 17;51(3):885-897. doi: 10.1039/d1dt03959h.
10
Probing platinum azido complexes by 14N and 15N NMR spectroscopy.通过 14N 和 15N NMR 光谱研究铂叠氮络合物。
Chemistry. 2011 Oct 17;17(43):12059-66. doi: 10.1002/chem.201101409. Epub 2011 Sep 16.

引用本文的文献

1
Protonation of Pt(IV) Anticancer Complexes Assayed by Vibrational Ion Spectroscopy.通过振动离子光谱法测定的铂(IV)抗癌配合物的质子化作用
Chempluschem. 2025 Jun;90(6):e202400754. doi: 10.1002/cplu.202400754. Epub 2025 Apr 3.
2
Stepwise optimization of tumor-targeted dual-action platinum(iv)-gemcitabine prodrugs.肿瘤靶向双功能铂(IV)-吉西他滨前药的逐步优化
Inorg Chem Front. 2023 Dec 6;11(2):534-548. doi: 10.1039/d3qi02032k. eCollection 2024 Jan 16.
3
An ultrasound-activatable platinum prodrug for sono-sensitized chemotherapy.
一种超声激活的顺铂前药用于声敏化疗。
Sci Adv. 2023 Jun 23;9(25):eadg5964. doi: 10.1126/sciadv.adg5964. Epub 2023 Jun 21.
4
Anticancer Activity, Reduction Mechanism and G-Quadruplex DNA Binding of a Redox-Activated Platinum(IV)-Salphen Complex.一种氧化还原激活型铂(IV)-席夫碱配合物的抗癌活性、还原机制和 G-四链体 DNA 结合。
Int J Mol Sci. 2022 Dec 8;23(24):15579. doi: 10.3390/ijms232415579.
5
A New Manganese Superoxide Dismutase Mimetic Improves Oxaliplatin-Induced Neuropathy and Global Tolerance in Mice.一种新型锰过氧化物歧化酶模拟物可改善奥沙利铂诱导的小鼠神经病变和整体耐受性。
Int J Mol Sci. 2022 Oct 26;23(21):12938. doi: 10.3390/ijms232112938.
6
Improvement of Kiteplatin Efficacy by a Benzoato Pt(IV) Prodrug Suitable for Oral Administration.通过一种适合口服的苯甲酸盐 Pt(IV)前药来提高 Kiteplatin 的疗效。
Int J Mol Sci. 2022 Jun 25;23(13):7081. doi: 10.3390/ijms23137081.
7
Improving the anticancer activity of platinum(iv) prodrugs using a dual-targeting strategy with a dichloroacetate axial ligand.使用二氯乙酸轴向配体的双靶向策略提高铂(IV)前药的抗癌活性。
RSC Adv. 2019 Jul 17;9(39):22240-22247. doi: 10.1039/c9ra03690c.
8
Click Pt(IV)-Carbohydrates Pro-Drugs for Treatment of Osteosarcoma.点击铂(IV)-碳水化合物前药用于骨肉瘤治疗
Front Chem. 2021 Dec 7;9:795997. doi: 10.3389/fchem.2021.795997. eCollection 2021.
9
Influence of the Number of Axial Bexarotene Ligands on the Cytotoxicity of Pt(IV) Analogs of Oxaliplatin.轴向贝沙罗汀配体数量对奥沙利铂铂(IV)类似物细胞毒性的影响。
Bioinorg Chem Appl. 2017;2017:4736321. doi: 10.1155/2017/4736321. Epub 2017 Jul 19.